VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).

Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug